Issue: December 2019

Read more

November 10, 2019
2 min read
Save

Tourniquet use did not change TKA surgical factors

Issue: December 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ran Schwarzkopf

DALLAS — A randomized controlled trial conducted to study results of total knee arthroplasty performed by four orthopedic surgeons at two sites with and without use of a tourniquet showed no negative impact postoperatively among patients who were randomized to undergo surgery with a tourniquet.

Perspective from Matthew S. Austin, MD

At the American Association of Hip and Knee Surgeons Annual Meeting, Ran Schwarzkopf, MD, presented findings of the analyses he and his colleagues did into some of the surgical variables that are theorized to be affected by tourniquet use during TKA, which included VAS pain scores, patient-reported outcomes, length of stay and readmissions.

“It is an ongoing study” of 228 patients, said Schwarzkopf, who presented results for 70 patients; 37 patients in the non-tourniquet group and 33 patients in the tourniquet group. The groups were similar in terms of their demographics, he noted.

All the tourniquets were inflated to 250 mm hg, Schwarzkopf said.

“When we look at surgical outcomes, surgical time, inpatient, morphine, length of stay, VAS scores on the day of surgery and 1 day, they’re equivalent. [There was] a little bit less blood loss ... in the tourniquet group. It was significant. I do not think it was clinically significant,” Schwarzkopf said.

“In conclusion, tourniquet use in this study, and other studies, does not change surgical factors,” he said.

Schwarzkopf added, “I think use of the tourniquet should be left to the surgeon.” – by Susan M. Rapp

 

Reference:

Padilla J, et al. Paper 8. Presented at: American Hip and Knee Surgeons Annual Meeting; Nov. 7-10, 2019; Dallas.

 

Disclosure: Schwarzkopf reports he receives stock or stock options from Gauss Surgical and is a paid consultant for and receives research support from Smith & Nephew.